Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
QGEN 
Qiagen NV (QGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: QGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $50.79
1 Year Target Price $50.79
| 6 | Strong Buy |
| 3 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.85% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.19B USD | Price to earnings Ratio 25.41 | 1Y Target Price 50.79 |
Price to earnings Ratio 25.41 | 1Y Target Price 50.79 | ||
Volume (30-day avg) 16 | Beta 0.68 | 52 Weeks Range 37.43 - 51.88 | Updated Date 12/7/2025 |
52 Weeks Range 37.43 - 51.88 | Updated Date 12/7/2025 | ||
Dividends yield (FY) 0.53% | Basic EPS (TTM) 1.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 19.58% | Operating Margin (TTM) 25.78% |
Management Effectiveness
Return on Assets (TTM) 8.19% | Return on Equity (TTM) 11.29% |
Valuation
Trailing PE 25.41 | Forward PE 16.95 | Enterprise Value 10630917410 | Price to Sales(TTM) 4.92 |
Enterprise Value 10630917410 | Price to Sales(TTM) 4.92 | ||
Enterprise Value to Revenue 5.13 | Enterprise Value to EBITDA 14.54 | Shares Outstanding 216841000 | Shares Floating 214657411 |
Shares Outstanding 216841000 | Shares Floating 214657411 | ||
Percent Insiders 0.45 | Percent Institutions 83.37 |
Upturn AI SWOT
Qiagen NV
Company Overview
History and Background
Qiagen NV is a global provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Founded in 1984 in Hilden, Germany, it became a public company in 1996. Significant milestones include its expansion into various diagnostic and research areas, strategic acquisitions, and its dual listing on the Frankfurt Stock Exchange and NASDAQ. Qiagen has evolved to become a key player in the life sciences and diagnostics industry, focusing on enabling customers to achieve breakthroughs in their scientific pursuits and clinical diagnoses.
Core Business Areas
- Sample Technologies: This segment provides a broad range of reagents, consumables, and instruments for the purification and isolation of nucleic acids (DNA and RNA) and proteins from various biological samples, such as blood, tissue, and cell cultures. These technologies are foundational for many molecular biology applications.
- Assay Technologies: This segment focuses on providing molecular testing solutions, including kits and instruments for detecting and analyzing specific genetic markers, pathogens, and other biomarkers. This includes applications in infectious disease testing, cancer diagnostics, and genetic analysis.
- Automation and Informatics: Qiagen offers automated solutions and software for sample processing, assay execution, and data analysis, aiming to improve efficiency, reproducibility, and throughput in molecular testing laboratories.
Leadership and Structure
Qiagen NV is led by a management board and overseen by a supervisory board. Key executives typically include a Chief Executive Officer (CEO), Chief Financial Officer (CFO), and heads of various business units and regions. The company operates through a global network of subsidiaries and offices.
Top Products and Market Share
Key Offerings
- Description: A widely used kit for the isolation of total DNA from various biological samples. It is a staple in research and diagnostic laboratories worldwide. Competitors include Thermo Fisher Scientific (with its GeneJET kits), Promega Corporation, and Roche.
- Market Share Data: Specific market share data for individual products is proprietary. However, Qiagen is a leading provider in the sample preparation market.
- Product Name 1: QIAamp DNA Mini Kit
- Description: An automated molecular diagnostic system designed for high-throughput testing of infectious diseases, genetic disorders, and other molecular targets. Competitors include Abbott Laboratories (with its m2000 system), Roche Diagnostics (with its cobas systems), and Hologic, Inc. (with its Panther system).
- Market Share Data: As a newer system, its market share is growing, but specific figures are not publicly disclosed. Qiagen aims to capture a significant portion of the automated molecular diagnostics market.
- Product Name 2: NeuMoDx 96 Integrated System
- Description: A flexible and efficient instrument for quantitative PCR (qPCR) and real-time PCR applications, used for gene expression analysis, pathogen detection, and genetic testing. Competitors include Thermo Fisher Scientific (Applied Biosystems), Bio-Rad Laboratories, and Agilent Technologies.
- Market Share Data: Qiagen holds a strong position in the qPCR instrument market.
- Product Name 3: Rotor-Gene Q Real-Time PCR Instrument
Market Dynamics
Industry Overview
Qiagen operates within the global life sciences tools and diagnostics market. This industry is characterized by continuous innovation, driven by advancements in genomics, molecular biology, and personalized medicine. Key trends include the increasing demand for rapid and accurate diagnostic tests, the growth of the infectious disease testing market, and the expansion of precision medicine in oncology. The market is highly competitive and requires significant investment in R&D.
Positioning
Qiagen is positioned as a leading provider of integrated solutions for molecular testing, from sample preparation to assay development and automation. Its competitive advantages include a broad product portfolio, a strong global presence, a well-established customer base in both research and clinical settings, and a focus on innovation and quality. The company's ability to offer both sample prep and assay technologies provides a unique value proposition.
Total Addressable Market (TAM)
The global market for molecular diagnostics and life science research tools is substantial and growing. Estimates vary, but the TAM is in the tens of billions of US dollars and is projected to continue expanding at a healthy CAGR. Qiagen is well-positioned to address a significant portion of this TAM, particularly in areas like sample preparation, molecular testing for infectious diseases, and cancer diagnostics.
Upturn SWOT Analysis
Strengths
- Broad and comprehensive product portfolio across sample preparation and assay technologies.
- Strong global sales and distribution network.
- Well-established brand reputation and customer loyalty.
- Significant R&D capabilities and pipeline of innovative products.
- Expertise in automation and informatics solutions.
Weaknesses
- Reliance on third-party suppliers for certain raw materials.
- Intense competition from larger, diversified healthcare companies.
- Potential for integration challenges with past acquisitions.
- Sensitivity to R&D spending cuts by academic institutions and pharmaceutical companies.
Opportunities
- Growing demand for molecular diagnostics, especially for infectious diseases and cancer.
- Expansion into emerging markets.
- Development of new assays for personalized medicine and companion diagnostics.
- Leveraging automation and AI to enhance laboratory workflows.
- Strategic partnerships and collaborations.
Threats
- Rapid technological advancements by competitors.
- Regulatory changes and reimbursement policies affecting diagnostics.
- Economic downturns impacting research and healthcare spending.
- Intellectual property disputes.
- Supply chain disruptions.
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Roche Holding AG (RHHBY)
- Abbott Laboratories (ABT)
- Bio-Rad Laboratories, Inc. (BIO)
- Illumina, Inc. (ILMN)
- Agilent Technologies, Inc. (A)
Competitive Landscape
Qiagen faces a highly competitive landscape. Its advantage lies in its comprehensive offering of sample preparation and assay technologies, often providing a 'one-stop-shop' for molecular testing needs. However, larger competitors like Thermo Fisher Scientific and Roche have broader portfolios and greater financial resources, potentially allowing them to outspend Qiagen on R&D and market penetration. Illumina dominates the sequencing market, posing a competitive threat in certain genomic applications. Qiagen's ability to innovate and execute on its strategy is crucial for maintaining and growing its market share.
Major Acquisitions
Exact Sciences Corporation (partial divestiture/partnership)
- Year: 2021
- Acquisition Price (USD millions):
- Strategic Rationale: Qiagen entered into a partnership with Exact Sciences, involving a co-exclusive license for certain technologies, which was part of Exact Sciences' acquisition of MDxHealth. This allowed Qiagen to expand its cancer diagnostics offerings.
BioServ
- Year: 2022
- Acquisition Price (USD millions):
- Strategic Rationale: Acquisition aimed at strengthening Qiagen's liquid biopsy capabilities and its position in the oncology market.
Growth Trajectory and Initiatives
Historical Growth: Qiagen has demonstrated historical growth driven by organic expansion and strategic acquisitions. Its growth has been fueled by the increasing adoption of molecular diagnostics and research technologies across various sectors.
Future Projections: Future growth projections for Qiagen are typically based on analyst estimates, considering market trends, product pipeline, and strategic initiatives. Analysts often project continued growth driven by advancements in personalized medicine, companion diagnostics, and automation.
Recent Initiatives: Recent strategic initiatives may include the acquisition of companies to expand its technology portfolio or market reach, investments in R&D for new product development, and efforts to strengthen its position in key diagnostic areas such as oncology and infectious diseases.
Summary
Qiagen NV is a strong player in the molecular diagnostics and life sciences tools market, with a broad product portfolio and global reach. Its strengths lie in its integrated sample and assay technologies. The company faces intense competition from larger, well-funded rivals. Continued innovation, strategic partnerships, and focus on emerging markets will be crucial for its sustained growth and success. Potential threats include rapid technological shifts and regulatory challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (e.g., 10-K, Annual Reports)
- Financial News Outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Market Research Reports (e.g., Grand View Research, Fortune Business Insights)
- Financial Data Aggregators (e.g., Yahoo Finance, Google Finance)
Disclaimers:
This JSON output is a structured representation of publicly available information about Qiagen NV. It is intended for informational purposes only and does not constitute financial advice. Market share data and acquisition prices are estimates and may not be precise. Users should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qiagen NV
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-06-28 | CEO, MD & Member of Management Board Mr. Thierry Bernard | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 5700 | Website https://www.qiagen.com |
Full time employees 5700 | Website https://www.qiagen.com | ||
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.